Longitude Capital
  • ABOUT
  • TEAM
  • PORTFOLIO
  • NEWS
  • CONTACT
  • LP LOGIN
Select Page

Kala Pharmaceuticals Announces New Drug Application For KPI-121 0.25% For Dry Eye Disease Has Been Accepted For Review By The U.S. Food And Drug Administration

by mparnell | Dec 26, 2018 | Portfolio News

Nabriva Therapeutics Announces Closing of up to a $75 million Term Loan

by mparnell | Dec 21, 2018 | Portfolio News

Aimmune Therapeutics Submits BLA to FDA for AR101 for the Treatment of Peanut Allergy in Children and Adolescents Ages 4–17

by mparnell | Dec 21, 2018 | Portfolio News

Nabriva Therapeutics Submits New Drug Applications to U.S. Food and Drug Administration for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults

by mparnell | Dec 20, 2018 | Portfolio News

Aimmune Therapeutics Announces IND Filing for AR201 for Egg Allergy and Exclusive Supply Agreement with Michael Foods

by mparnell | Dec 20, 2018 | Portfolio News

« Older Entries

Media Contact

Maggie Jamison

mjamison@longitudecapital.com

650-854-5700

  • Facebook
  • Twitter
  • Google
  • RSS
footer-logo

LP Login

© 2023 Longitude Capital. All rights reserved.
  • Privacy Policy
  • Disclaimer